Help your physicians catch medication problems before the visit.
Tachyra reviews each patient’s history, full medication list and lab trends ahead of the appointment, and gives the physician a short summary to review and approve. We are inviting a Florida Medicare Advantage plan to co-design our pilot, so we measure the outcomes your plan pays for.
Medication harm and missed diagnoses drive avoidable ER visits and admissions.
Many members see several prescribers, so no single physician sees the whole medication list. Duplications and risky combinations slip through, and physicians have little time per visit to review a full history.
A second set of eyes before the patient walks in. The physician decides.
Every recommendation goes through physician review and approval, and every decision is recorded. Tachyra never diagnoses or prescribes on its own.
| Ranked list of possible diagnoses | Working in prototype |
| Medication interaction and duplication flags | Working in prototype |
| Tracking each patient against their own baseline | In development |
| Treatment comparisons | In development |
| Alerts inside the physician’s EHR | Planned |
Tachyra is in pilot development, with pilot readiness targeted for mid-2027.
A pilot partnership, measured your way
What we ask of your plan
- Help define the outcome measures: avoidable ER visits, admissions, medication harm, and medications safely stopped.
- Introduce us to two or three in-network primary-care groups serving many of your members.
- Share de-identified claims data for those practices, under a business associate agreement.
What your plan gets
- Results on your own members, measured the way you measure value.
- First access on preferred terms if the pilot succeeds, including sponsored licenses for in-network physicians or per-member pricing.
- A partner focused on medication safety for older adults, with the physician in charge of every decision.
Tachyra Diagnostics, Inc. is a Delray Beach, Florida company developing AI clinical decision support for physicians. Features described are planned capabilities unless marked as working in the prototype; availability will be confirmed as each is validated.